Literature DB >> 10589544

Prevalence of chronic inflammatory demyelinating polyneuropathy in New South Wales, Australia.

J G McLeod1, J D Pollard, P Macaskill, A Mohamed, P Spring, V Khurana.   

Abstract

A prevalence study of chronic inflammatory demyelinating polyneuropathy (CIDP) was performed in New South Wales (NSW), Australia, with a prevalence day of August 6, 1996, which coincided with a national census. The population of NSW was 5,995,544, and the crude prevalence of CIDP was 1.9 per 100,000 population. It was higher in male patients than in female patients, and the age-specific prevalence reached a maximum of 6.7 per 100,000 population in the 70- to 79-year-old age group. The prevalence in the city of Newcastle, with a population of 448,663, was 2.0 per 100,000 population and is representative of the whole of NSW. The estimated crude annual incidence was 0.15 per 100,000 population. The mean age of onset was 47.6 years (median, 53.5 years), 51% of patients had a relapsing-remitting course, the mean duration on prevalence day was 7.1 years (median, 5 years), and 87% of patients were able to walk without walking aids or other assistance.

Entities:  

Mesh:

Year:  1999        PMID: 10589544

Source DB:  PubMed          Journal:  Ann Neurol        ISSN: 0364-5134            Impact factor:   10.422


  31 in total

Review 1.  Chronic inflammatory demyelinative polyneuropathy.

Authors:  Gérard Said
Journal:  J Neurol       Date:  2002-03       Impact factor: 4.849

Review 2.  Management of chronic inflammatory demyelinating polyradiculoneuropathy.

Authors:  Richard A C Hughes
Journal:  Drugs       Date:  2003       Impact factor: 9.546

3.  Pathogenesis and treatment of immune-mediated neuropathies.

Authors:  Helmar C Lehmann; Gerd Meyer Zu Horste; Bernd C Kieseier; Hans-Peter Hartung
Journal:  Ther Adv Neurol Disord       Date:  2009-07       Impact factor: 6.570

4.  Incidence and prevalence of CIDP and the association of diabetes mellitus.

Authors:  R S Laughlin; P J Dyck; L J Melton; C Leibson; J Ransom; P J B Dyck
Journal:  Neurology       Date:  2009-07-07       Impact factor: 9.910

5.  A case of cauda equina syndrome in early-onset chronic inflammatory demyelinating polyneuropathy clinically similar to charcot-marie-tooth disease type 1.

Authors:  Seung Eun Lee; Seung Won Park; Sam Yeol Ha; Taek Kyun Nam
Journal:  J Korean Neurosurg Soc       Date:  2014-06-30

Review 6.  Chronic inflammatory demyelinating polyneuropathies: current treatment strategies.

Authors:  Thomas B Toothaker; Thomas H Brannagan
Journal:  Curr Neurol Neurosci Rep       Date:  2007-01       Impact factor: 5.081

7.  Subcutaneous vs intravenous administration of immunoglobulin in chronic inflammatory demyelinating polyneuropathy: an Italian cost-minimization analysis.

Authors:  Carlo Lazzaro; Leonardo Lopiano; Dario Cocito
Journal:  Neurol Sci       Date:  2014-01-28       Impact factor: 3.307

8.  Cost-utility of Intravenous Immunoglobulin (IVIG) compared with corticosteroids for the treatment of Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) in Canada.

Authors:  Gord Blackhouse; Kathryn Gaebel; Feng Xie; Kaitryn Campbell; Nazila Assasi; Jean-Eric Tarride; Daria O'Reilly; Colin Chalk; Mitchell Levine; Ron Goeree
Journal:  Cost Eff Resour Alloc       Date:  2010-06-17

Review 9.  Newer therapeutic options for chronic inflammatory demyelinating polyradiculoneuropathy.

Authors:  Krista Kuitwaard; Pieter A van Doorn
Journal:  Drugs       Date:  2009-05-29       Impact factor: 9.546

10.  Idiopathic chronic inflammatory demyelinating polyneuropathy: an epidemiological study in Italy.

Authors:  A Chiò; D Cocito; E Bottacchi; C Buffa; M Leone; F Plano; R Mutani; A Calvo
Journal:  J Neurol Neurosurg Psychiatry       Date:  2007-05-10       Impact factor: 10.154

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.